Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Feb 14, 2021; 27(6): 501-512
Published online Feb 14, 2021. doi: 10.3748/wjg.v27.i6.501
Table 5 Performance of each serum tumor maker in predicting advanced mucinous cystic neoplasms

Overall
Benign
Advanced
P value1
CA19-9 (n = 31)
Median, IQR (U/mL)14.7 (7.3-108.1)7.73 (5.63-24.2)157 (15.7-1100)0.001
≥ 37/< 37 U/mL10/262/218/50.003
CEA (n = 31)
Median, IQR (ng/mL)1.5 (1.05-2.58)1.5 (1.0-1.87)2.56 (1.31-5.57)0.004
≥ 5/< 5 ng/mL3/330/233/100.04
CA125 (n = 26)
Median, IQR (U/mL)14.5 (10.0-25.7)14.4 (9.2-20.1)68.6 (11.9-125)< 0.0001
≥ 35 /< 35 U/mL5/210/195/2< 0.0001
CA724 (n = 20)
Median, IQR (U/mL)1.5 (0.96-2.7)1.52 (0.99-2.24)1.53 (0.8-6.8)0.538
≥ 9.8/< 9.8 U /mL1/191/140/51.00
CA242 (n = 3)
Median, IQR (U/mL)2.39 (0.1)1.25 (0.1)35.35Not applicable
≥ 20/< 20 U/mL1/20/21/00.333